title: Safety and outcome after thrombolysis in stroke patients with mild symptoms.
abstract: BACKGROUND
  Thrombolytic therapy is frequently withheld in patients with minor stroke symptoms. However, recent studies demonstrate that a substantial proportion of these patients dies or remains permanently disabled because of underestimation of symptom severity at baseline or secondary deterioration. We aimed to assess the safety and outcome of thrombolysis therapy in patients with minor but disabling stroke symptoms.
  
  
  METHODS
  32 patients presenting with mild symptoms were treated with intravenous recombinant tissue-type plasminogen activator between April 2006 and April 2008. Data were extracted from a prospectively collected database. Baseline demographic data, and clinical, laboratory and imaging findings were analyzed. Outcome was assessed using the modified Rankin Scale (mRS) score at 3 months and was dichotomized into favorable (mRS 0-1) versus unfavorable (mRS 2-6).
  
  
  RESULTS
  In the majority of patients, the left hemisphere was affected, with aphasia representing the most common symptom leading to treatment decision. The frequency of perfusion lesion (46%) and vessel occlusion (35%) at baseline was high but had no effect on the outcome at 3 months in our series of treated patients. Outcome was favorable in 94% of patients, and 47% recovered without any persisting symptom. Only one asymptomatic and no symptomatic hemorrhage was observed.
  
  
  CONCLUSIONS
  Our data support current guidelines and international licenses which give no lower National Institutes of Health Stroke Scale (NIHSS) limit for intravenous thrombolysis (IVT). Considering the accumulating evidence that the natural course in patients with mild symptoms is not as favorable as often assumed and taking the low risk of bleeding in those patients into account, patients with mild but disabling symptoms should be treated with IVT regardless of their baseline NIHSS score.
authors.affiliation: Department of Neurology, University of Erlangen, Schwabachanlage 6, Erlangen, Germany. martin.koehrmann@uk-erlangen.de
authors.forename: M
authors.initials: M
authors.lastname: Köhrmann
authors.forename: T
authors.initials: T
authors.lastname: Nowe
authors.forename: H B
authors.initials: HB
authors.lastname: Huttner
authors.forename: T
authors.initials: T
authors.lastname: Engelhorn
authors.forename: T
authors.initials: T
authors.lastname: Struffert
authors.forename: R
authors.initials: R
authors.lastname: Kollmar
authors.forename: M
authors.initials: M
authors.lastname: Saake
authors.forename: A
authors.initials: A
authors.lastname: Doerfler
authors.forename: S
authors.initials: S
authors.lastname: Schwab
authors.forename: P D
authors.initials: PD
authors.lastname: Schellinger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005858:Germany; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator